Literature DB >> 18246052

Interphase cytogenetic analysis with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in 11 tumors from a patient with bilateral renal oncocytosis.

Paolo Cossu-Rocca1, John N Eble, Shaobo Zhang, Stephen M Bonsib, Guido Martignoni, Matteo Brunelli, Liang Cheng.   

Abstract

Renal oncocytosis is characterized by the presence of multiple tumors with oncocytic features, often associated with small clusters of tubule-like structures with oncocytic change. The morphologic features of the oncocytic nodules encompass a spectrum of appearances, with patterns typical of renal oncocytoma or classic chromophobe renal cell carcinoma, as well as 'hybrid' tumors with features resembling both oncocytoma and chromophobe renal cell carcinoma. We utilized interphase cytogenetic methods to study 11 tumors from the kidneys of a 45-year-old woman. The tumors included morphologically classical oncocytomas and 'hybrid' tumors with features reminiscent of chromophobe carcinoma. The kidneys also showed foci of oncocytic change in renal tubules. Fluorescence in situ hybridization was performed with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in each of the 11 tumors to determine whether or not there were losses of the chromosomes that are most frequently lost in chromophobe renal cell carcinomas. Neoplastic nuclei from each tumor were evaluated for the number of hybridization signals and scored according to the percentage of nuclei with one, two, and three or more signals. The normal renal parenchyma surrounding the tumors was used as control tissue. All 11 tumors from this patient with renal oncocytosis showed no loss of any of the chromosomes 1, 2, 6, 10, or 17, a pattern identical to that found in normal control tissues. These observations weigh against the concept that hybrid tumors of oncocytosis are closely related to chromophobe renal cell carcinoma.

Entities:  

Mesh:

Year:  2008        PMID: 18246052     DOI: 10.1038/modpathol.2008.16

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Renal oncocytosis: management and clinical outcomes.

Authors:  Ari Adamy; William T Lowrance; David S Yee; Kian Tai Chong; Melanie Bernstein; Satish K Tickoo; Jonathan A Coleman; Paul Russo
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

2.  Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma.

Authors:  B Amend; J Hennenlotter; M Scharpf; S Kruck; U Kuehs; E Senger; A S Merseburger; M A Kuczyk; K D Sievert; A Stenzl; J Bedke
Journal:  World J Urol       Date:  2011-08-07       Impact factor: 4.226

3.  Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.

Authors:  Fredrik Petersson; Zoran Gatalica; Petr Grossmann; Maria Delia Perez Montiel; Isabel Alvarado Cabrero; Stela Bulimbasic; Anthony Swatek; Lubomir Straka; Tomas Tichy; Milan Hora; Naoto Kuroda; Ben Legendre; Michal Michal; Ondrej Hes
Journal:  Virchows Arch       Date:  2010-03-19       Impact factor: 4.064

4.  Dysplastic ("in-situ") Lesions in multofocal renal oncocytomas (oncocytosis).

Authors:  Jiaoti Huang; Peng Lee; Yoshiki Mikami; Jonathan Melamed
Journal:  Int J Clin Exp Pathol       Date:  2009-06-18

Review 5.  [The diagnostic and therapeutic challenges of bilateral renal oncocytosis : Illustrative case presentations and a review of the literature].

Authors:  M Janssen; M Eckerl; J Moersler; M Rotter; M May; C Gilfrich
Journal:  Urologe A       Date:  2016-07       Impact factor: 0.639

6.  EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma.

Authors:  Khaleel I Al-Obaidy; Julia A Bridge; Liang Cheng; Janos Sumegi; Victor E Reuter; Ryma Benayed; Meera Hameed; Sean R Williamson; Ondrej Hes; Fatimah I Alruwaii; Jeremy P Segal; Pankhuri Wanjari; Muhammad T Idrees; Mehdi Nassiri; John N Eble; David J Grignon
Journal:  Mod Pathol       Date:  2021-06-07       Impact factor: 7.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.